Cytovia Therapeutics

Cytovia Therapeutics is committed to developing transformative cancer immunotherapies, addressing some of the most challenging unmet medical needs, including the prevention of cancer recurrence and metastasis. Cytovia focuses on natural killer (NK) cell biology and applies precision medicine tools to develop the right treatment for the right patient at the right stage of the disease. Cytovia's key areas include an iPSC platform for NK cell therapy, gene-edited CARs to enhance targeting of NK cells, and multifunctional NK engager antibodies. Currently, the most advanced programs are two multifunctional antibody products, CYT-303 and CYT-338.